Nephros, Inc. (OTC: NEPH) A reader of StocksHaven Investments by the name of Michael Sklar has contributed the following article regarding Nephros, Inc. The article outlines one of the most undervalued BioPharma companies around, at only $1.08 PPS with three pending FDA decisions. If you are an avid investor of pre-PDUFA companies, StocksHaven Investments highly [...]



